QCG
AXSM icon

Quadrant Capital Group’s Axsome Therapeutics AXSM Stock Holding History

Quadrant Capital Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8K Hold
135
– – ﹤0.01% 1962
2025
Q4 		$24.7K Hold
135
– – ﹤0.01% 1925
2025
Q3 		$16.4K Buy
+135
New +$15.2K ﹤0.01% 2010
2025
Q2 		– Sell
-135
Closed -$15.7K – 1458
2025
Q1 		$15.7K Hold
135
– – ﹤0.01% 2099
2024
Q4 		$11.4K Hold
135
– – ﹤0.01% 2083
2024
Q3 		$12.1K Hold
135
– – ﹤0.01% 2088
2024
Q2 		$10.9K Hold
135
– – ﹤0.01% 2092
2024
Q1 		$10.8K Hold
135
– – ﹤0.01% 2077
2023
Q4 		$10.7K Sell
135
-29
-18% -$1.94K ﹤0.01% 2041
2023
Q3 		$11.5K Buy
164
+24
+17% +$1.79K ﹤0.01% 1938
2023
Q2 		$10.1K Buy
140
+5
+4% +$369 ﹤0.01% 1990
2023
Q1 		$8.33K Hold
135
– – ﹤0.01% 2099
2022
Q4 		$10.4K Hold
135
– – ﹤0.01% 1929
2022
Q3 		$6K Hold
135
– – ﹤0.01% 2056
2022
Q2 		$5K Buy
135
+70
+108% +$2.21K ﹤0.01% 1937
2022
Q1 		$3K Sell
65
-142
-69% -$4.4K ﹤0.01% 2030
2021
Q4 		$8K Buy
207
+7
+4% +$258 ﹤0.01% 1707
2021
Q3 		$7K Buy
200
+92
+85% +$3.58K ﹤0.01% 1736
2021
Q2 		$7K Sell
108
-3
-3% -$180 ﹤0.01% 1709
2021
Q1 		$6K Buy
111
+11
+11% +$774 ﹤0.01% 1699
2020
Q4 		$8K Hold
100
– – ﹤0.01% 1473
2020
Q3 		$7K Buy
+100
New +$7.79K ﹤0.01% 1356

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's AXSM Position: Q1 2026 in Review

Quadrant Capital Group held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 135 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1962.

Quadrant Capital Group first reported a position in AXSM in Q3 2020 and has held it in 22 quarters since. The position peaked at $24.7K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Quadrant Capital Group held 135 shares of Axsome Therapeutics worth $22.8K as of Q1 2026.
  • Quadrant Capital Group left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1962 holding.
  • Quadrant Capital Group first reported a position in Axsome Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Quadrant Capital Group's Axsome Therapeutics position peaked at $24.7K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.